These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 6601736

  • 1. Subsets of oncofetal antigen-induced T-cells: ability to mediate antitumor immune response.
    Gautam S, Deodhar SD.
    J Natl Cancer Inst; 1983 May; 70(5):923-30. PubMed ID: 6601736
    [Abstract] [Full Text] [Related]

  • 2. T-cell-mediated antitumor immune response induced by oncofetal antigens.
    Gautam S, Deodhar SD.
    J Natl Cancer Inst; 1981 Oct; 67(4):939-45. PubMed ID: 6974275
    [Abstract] [Full Text] [Related]

  • 3. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S, Chou T, Rosenberg SA.
    Cancer Res; 1987 Mar 01; 47(5):1354-60. PubMed ID: 3102046
    [Abstract] [Full Text] [Related]

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM, Engel AM.
    APMIS Suppl; 2003 Mar 01; (106):1-46. PubMed ID: 12739251
    [Abstract] [Full Text] [Related]

  • 5. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct 01; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 6. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 01; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 7. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
    Fuyama S, Yamamoto H, Arai S.
    Cancer Res; 1985 Sep 01; 45(9):4103-8. PubMed ID: 3875404
    [Abstract] [Full Text] [Related]

  • 8. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E, Mokyr MB.
    Cancer Res; 1988 Sep 01; 48(17):4834-42. PubMed ID: 3261626
    [Abstract] [Full Text] [Related]

  • 9. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep 01; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 10. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.
    Biol Blood Marrow Transplant; 2004 Aug 01; 10(8):524-33. PubMed ID: 15282530
    [Abstract] [Full Text] [Related]

  • 11. Analysis of murine oncofetal antigens as tumor-associated transplantation antigens.
    Chism SE, Wallis S, Burton RC, Warner NL.
    J Immunol; 1976 Nov 01; 117(5 Pt.2):1870-7. PubMed ID: 993583
    [Abstract] [Full Text] [Related]

  • 12. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
    Norbury KC.
    Cancer Res; 1977 May 01; 37(5):1408-15. PubMed ID: 66982
    [Abstract] [Full Text] [Related]

  • 13. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation.
    Treves AJ, Cohen IR, Feldman M.
    Isr J Med Sci; 1976 May 01; 12(4-5):369-84. PubMed ID: 1084880
    [Abstract] [Full Text] [Related]

  • 14. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W, He L, Cao X.
    Zhonghua Yi Xue Za Zhi; 1999 Mar 01; 79(3):170-3. PubMed ID: 11601032
    [Abstract] [Full Text] [Related]

  • 15. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.
    J Clin Invest; 1998 Jan 15; 101(2):429-41. PubMed ID: 9435316
    [Abstract] [Full Text] [Related]

  • 16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 18. Role of T-cells in the mechanism of reactivity of the microplate leukocyte adherence inhibition assay.
    Raina S, Russo AJ, Jenkins D, Goldrosen MH.
    Cancer Res; 1981 Oct 15; 41(10):3950-5. PubMed ID: 6456811
    [Abstract] [Full Text] [Related]

  • 19. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May 15; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 20. Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.
    Carter RH, Drebin JA, Schatten S, Perry LL, Greene MI.
    J Immunol; 1983 Feb 15; 130(2):997-1002. PubMed ID: 6184410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.